The combination of ixabepilone and carboplatin was investigated in a phase II study of 103 patients with hormone receptor-positive (HR D ) and triple negative (TN) metastatic breast cancer (MBC) previously treated with 0 to 2 chemotherapy regimens for MBC. ORRs were similar in taxane-pretreated patients (ORR, 31.4% and 28.6% for HR þ and TN patients, respectively). The median OS was 17.9 months for HR þ patients and 12.5 months for TN patients. The median PFS was similar for both groups at 7.6 months. Grade 3/4 nonhematologic toxicities included neuropathy (9%) and fatigue (8%). Nine patients developed grade 3/4 neuropathy, 7 of whom had received previous taxane treatment. Conclusion: Ixabepilone plus carboplatin is active even in later-line HR þ and TN disease. Toxicities were manageable without cumulative myelosuppression. This combination is a reasonable option for those patients with MBC who require combination chemotherapy.
Introduction
According to the World Health Organization global health estimates, breast cancer remains the most common cancer diagnosed in women worldwide. 1 In 2011, > 500,000 women died of breast cancer. In the United States, breast cancer is the most common cancer diagnosed in women and the second leading cause of cancer deaths. According to the Surveillance, Epidemiology, and End Results Program, registry 18, only 6% of women will be diagnosed with de novo metastatic breast cancer (MBC), and the 5-year survival rates for these women have been roughly 26%. 2 Fewer data are available regarding the percentage of women alive at 5 years who were initially diagnosed with early-stage disease and later developed relapse with metastatic disease. However, the reported estimates range from 20% to 30%, with a median survival of only 20 months. 3 MBC remains incurable, and most breast cancer-related deaths are from metastatic disease. Currently, no standard algorithm is available for treating MBC. Endocrine therapies, at least until the development of resistance, are the mainstay for hormone receptor-positive (HR þ ) disease, with the caveat that rapidly progressive disease might still be best addressed with chemotherapy. In contrast, for patients with triple negative (TN) metastatic disease, chemotherapy remains the only treatment option. The current guidelines have recognized that combination therapies tend to offer greater response rates. However, this often comes at the cost of increased toxicity and without clear evidence of a survival benefit. 4 The preferred recommendation is for sequential single-agent chemotherapy; however, patients with symptomatic and/or rapidly progressive disease will often be best served by combination chemotherapy. 4 Combinations, when required, have varying toxicity profiles and offer treating physicians and patients therapeutic options. New effective and safe alternatives are required for this difficult to treat population. Ixabepilone is a novel microtubule-targeting epothilone. It binds to b-tubulin but in a distinct manner compared with taxanes and has reduced susceptibility to efflux pumps such as P-glycoprotein and multidrug resistance-associated protein-1, offering the potential for reduced drug resistance. 5 As a single agent, ixabepilone has been approved in the United States for the treatment of MBC previously treated with an anthracycline, taxane, and capecitabine. In a variety of phase II settings, objective response rates (ORRs) with singleagent ixabepilone have ranged from 11.5% to 42%. [6] [7] [8] Ixabepilone has also been approved for use in combination with capecitabine for the treatment of locally advanced breast cancer and MBC after failure of an anthracycline and a taxane. This approval was based on the findings from 2 large randomized phase III trials demonstrating improved progression-free survival (PFS) for the combination (6.2 months and 5.8 months) compared with single-agent capecitabine (4.2 months in both trials). 9, 10 Ixabepilone as a single agent
and combined with capecitabine has demonstrated activity in both difficult to treat TN breast cancer and HR þ disease.
Carboplatin is a highly effective cytotoxic platinum agent that causes DNA adducts and cross-links, resulting in apoptosis in a variety of cell types. 11 When combined with paclitaxel, the ORR in MBC in 2 separate phase II studies in the first-line setting was 62%. 12, 13 Developing a combination of a microtubule stabilizing agent with enhanced ability to evade multiple drug resistance mechanisms with a platinum agent, specifically carboplatin, which has proven antitumor activity in TN MBC, was the impetus behind the present study. In addition, tumors with reduced DNA repair capability, including a subset of TN breast cancer, appear to be especially sensitive to platinum-induced DNA damage, making this an appealing agent to partner with ixabepilone. A previous phase I study demonstrated the feasibility and tolerability of this combination using a similar schedule.
14 Patients with symptomatic MBC are in need of novel, tolerable, and effective treatment options. We present our results from the phase II study of the combination of ixabepilone and carboplatin for women with metastatic HR þ and TN breast cancer. Ixabepilone Plus Carboplatin for HER2 L MBC board with jurisdiction over the US Oncology Network approved the present study, and all patients provided written informed consent before enrollment. All patient records were stored in accordance with the Health Insurance Portability and Accountability Act regulations.
Patients and Methods

Patients
Treatment
The patients were treated with ixabepilone 20 mg/m 2 intravenously given over 60 minutes and carboplatin (area under the curve, 2.5) intravenously given over ! 15 minutes on days 1 and 8 of a 21-day cycle until progressive disease or intolerable toxicity developed.
Patients who experienced a hypersensitivity reaction in any cycle were premedicated in subsequent cycles with a corticosteroid and an H1 and H2 antagonist.
Response Assessment
Chest radiography, computed tomography of the chest, abdomen, and pelvis, magnetic resonance imaging, and/or bone scan were permitted for radiologic tumor assessment and were obtained within 4 weeks before study treatment was initiated. The same modality was used throughout the study, and the same imaging equipment was used each time the tumor was assessed whenever possible. Radiologic assessment of measureable disease was performed every 6 weeks through cycle 6 and then every third cycle (after cycles 9, 12, 15, 18, and so forth) thereafter. Disease response and progression were evaluated using the international criteria published by the Response Evaluation Criteria In Solid Tumors Committee, version 1.1.
Sample Size and Statistical Analysis
Using a 1-sample binomial exact method (STPlan Software) with an a of 0.05, a power of 80%, and 1-sided significance level, 103 patients with MBC (54 HR þ and 49 TN) were enrolled to test the hypothesis that the ORR would increase from 18% to 34% in HR þ patients and from 15% to 30% in TN patients treated with ixabepilone plus carboplatin. [6] [7] [8] The 18% and 15% response rates were our estimates of the activity of single-agent ixabepilone in patients with HR þ and TN MBC, respectively. We assumed that most patients would have been previously treated with a taxane. The ORR was determined per protocol according to the evaluable population (all eligible patients who met the efficacy analyses requirements and had received ! 1 dose of study drug). A 2-sided 95% confidence interval was calculated separately for the response rates in the ER þ and TN cohorts. Among the patients who achieved an objective response, the duration of response was measured from the first date the CR or PR was documented to the date of progression or death or the date of the last follow-up visit. OS was defined as the interval from the date of registration to the date of death or last visit, and PFS was calculated from the date of registration to the date of progression or death from any cause or the date of the last followup visit if the patient was alive and without disease progression. These estimates were determined using the Kaplan-Meier method in the intent to treat (ITT) population. 15 The toxicity of ixabepilone plus carboplatin was evaluated in the safety population (all patients who had received ! 1 dose of the study regimen). SAS software, version 9.2, was used to perform the analyses. R software, version 3.0.1, was applied to prepare the data for the survival analyses. Most patients (58%) required both a dose delay and a dose reduction. Approximately 21% required a dose delay of ! 1 cycles only and 6% required ! 1 dose reductions only. The major toxicities observed in the safety population are listed in Table 7 . The main toxicities were hematologic, with grade 3/4 neutropenia occurring in nearly 50% of patients. One neutropenic sepsis-related death occurred during the study. Seventy patients in the study had previously been treated with a taxane. In total, 9 patients (9%) developed grade 3/4 neuropathy. Seven of these patients had been previously treated with a taxane, for a 10% rate of grade 3/4 neuropathy in the taxane-pretreated population. Other significant (grade 3/4) toxicities included fatigue (8%), nausea (6%), diarrhea (6%), and vomiting (5%).
Results
From
Discussion
No standard algorithm is available for the use of chemotherapeutic agents in the treatment of MBC. 4 Combination therapy is typically reserved for symptomatic patients or those with rapidly progressive disease. The combination of ixabepilone and carboplatin in the present study was found to be an active and tolerable platinum-based doublet. For many patients in the present study, 50% of HR þ and 25% of TN patients, the study treatment was their second-line or later therapy for MBC, and the combination showed substantial activity in these pretreated patients. 
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Additionally, antitumor activity was maintained in the taxanepretreated patients. The associated ORRs were similar to those observed for the overall population, with an ORR of 31.4% and 28.6% and CBR of 51.4% and 40% in the HR þ and TN patients, respectively. The 31% ORR observed with the combination of ixabepilone and carboplatin in the study is comparable to that described for a variety of combination therapy regimens for MBC in similar settings (excluding first-line therapy studies). The combination of docetaxel and capecitabine in largely taxane-naive patients from 2 phase III studies demonstrated ORRs of 32% and 42%. 16, 17 The platinumcontaining doublet of gemcitabine and carboplatin is a none alopecia-inducing regimen that has been evaluated in a variety of phase II and III MBC populations. [18] [19] [20] [21] [22] [23] In these trials, most participants had been pretreated with a taxane. The response rates for this combination ranged from 27% to 34%, and responses were observed in the taxane-naive and taxane-pretreated patients. Loesch et al 20 evaluated the ORR with gemcitabine/carboplatin in a cohort of taxane-pretreated patients stratified by HR status. HR À , taxanepretreated patients had a higher ORR of 38.9% compared with HR þ taxane-pretreated patients, who had an ORR of 27%. These findings are roughly similar to our findings of an approximate 30% ORR in TN and HR þ taxane-pretreated patients. Hematologic toxicity, especially cumulative thrombocytopenia, can be a doseand treatment-limiting consequence of combined gemcitabine and carboplatin therapy. Carboplatin, when paired with paclitaxel, in contrast to gemcitabine, is platelet sparing. 24 The incidence of grade 3 or 4 thrombocytopenia with the combination of ixabepilone and carboplatin in our study was low at 5%, suggesting that ixabepilone is also platelet sparing. Two large phase III studies assessed the combination of ixabepilone (40 mg/m 2 every 3 weeks) and capecitabine in anthracyclineand taxane-pretreated or anthracycline-and taxane-refractory populations and demonstrated an ORR of 43% and 35%, respectively. 9,10 The development of peripheral neuropathy was common; approximately 66% of patients developed any grade and approximately 23% of patients developed grade 3/4 sensory neuropathy in both studies. Other significant nonhematologic toxicities included hand-foot syndrome, nausea, vomiting, fatigue, and diarrhea. A retrospective combined analysis performed of these 2 phase III trials evaluating combined ixabepilone and capecitabine assessed the efficacy in patients requiring dose reductions. 25 Of the patients who received ! 4 cycles, 73.5% required ! 1 dose reduction, and almost 40% required a dose reduction in the first 4 cycles. The efficacy, however, was maintained even in those patients requiring early dose reductions. Most patients who received ixabepilone and carboplatin in our study also required ! 1 dose reduction or dose delay, or both; however, the data from the previous study suggest that careful dose modification might not necessarily hinder the response.
The PFS with the combination of ixabepilone and carboplatin was 7.6 months and did not vary by TN or HR þ status. This compares favorably with other combination regimens. In the ixabepilone and capecitabine trials, the PFS for the combination arms was 6.2 and 5.8 months. 9, 10 In a phase III study comparing gemcitabine combined with docetaxel versus capecitabine with docetaxel, the PFS was approximately 8 months for both cohorts. 17 In the phase II trial comparing the combination arm of docetaxel plus capecitabine versus single-agent capecitabine, the time to progression for the combination arm was 6.1 months. 16 In addition, in our study, 8 TN patients (16.3%) and 10 HR þ patients (18.5%) experienced a long duration of PFS with therapy (> 12 months). All the TN patients with PFS of ! 12 months had received the study therapy as first-line treatment, and 2 were also chemotherapy-naive. Seven of the HR þ patients with a PFS of ! 12 months had also received the study treatment as front-line therapy in the metastatic setting, and 2 were also chemotherapy-naive. However, 2 HR þ patients with ! 12-month PFS had received the study therapy as second-line treatment and 1 as third-line therapy. One second-line HR þ patient and the third-line patient had a PFS interval of 27.2 and 22.9 months, respectively. Also, 6 HR þ patients and 3 TN patients remained in the study for > 18 months. Identifying the factors supportive of a long duration of response to this therapy could be useful. Tissue was obtained with enrollment and will be 
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Choosing a combination regimen for a patient with metastatic disease requires balancing the need for cytoreduction against toxicity. Gemcitabine and carboplatin causes little or no alopecia or neuropathy. However, myelosuppression is often cumulative and dose-and/or treatment-limiting. The ixabepilone and carboplatin combination has manageable hematologic and neurologic toxicity, with 9% of patients developing grade 3/4 neuropathy, of whom 7 had previously received a taxane. Neuropathy was, for the most part, manageable even in the taxane-pretreated patients, with a 10% rate of grade 3/4 neuropathy. This compares favorably with first-line paclitaxel and carboplatin in MBC cancer patients in whom grade 34 neuropathy rates have ranged from 11% to 16%.
12,13
Conclusion
The present phase II study was conducted in community oncology settings. Toxicities, although frequent, were manageable with dose reductions and delays. The combination of ixabepilone and carboplatin was active in both TN and HR þ MBC patients and offers an additional treatment option in the advanced setting.
Clinical Practice Points
The treatment of hormone-refractory or TN MBC remains challenging, and additional effective, tolerable therapeutic options are needed. Ixabepilone and carboplatin have nonoverlapping mechanisms of cytotoxicity and have each demonstrated single-agent activity in MBC, providing the impetus to study this combination in HR þ / HER2
À and TN MBC.
In the present phase II study, the combination of ixabepilone plus carboplatin produced objective responses in approximately one third of patients, and the ORR did not appear to be affected by previous taxane therapy.
The PFS compared favorably with that of other cytotoxic combination regimens in use for MBC.
Toxicities were manageable without cumulative myelosuppression; the most common grade 3/4 nonhematologic adverse events were neuropathy and fatigue. This regimen provides an additional active option for patients with hormone-refractory or TN MBC who require combination chemotherapy. 
